LÄKEMEDELSVERKET
MEDICAL PRODUCTS AGENCY

Public Assessment Report
Scientific discussion

Salipra
(ipratropium bromide, salbutamol sulphate)

Asp no: 2013-1475

This module reflects the scientific discussion for the approval of Salipra. The procedure was finalised on 2015-02-26. For information on changes after this date please refer to the module 'Update'.

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.mpa.se E-mail: registrator@mpa.se

I. INTRODUCTION

The application for Salipra, 0.5 mg/2.5 mg, nebuliser solution, is a hybrid application made according to Article 10(3) of Directive 2001/83/EC. The applicant, Alternova A/S, applies for a marketing authorisation in Sweden through a National Procedure.

The reference medicinal product chosen for the purposes of establishing the expiry of the data protection period is Combivent, 0,5 mg/2,5 mg, lösning för nebulisator, authorised in Sweden since 1995, with Boehringer Ingelheim Limited, UK, as marketing authorisation holder.

For approved indications, see the Summary of Product Characteristics.

II. QUALITY ASPECTS

II.1 Introduction

Salipra is presented in the form of nebuliser solution containing 0.52 mg of ipratropium bromide monohydrate which corresponds to 0.5 mg ipratropium and 3 mg salbutamol sulphate which corresponds to 2.5 mg salbutamol. The excipients are sodium chloride, sulfuric acid and water for injections. The solution is filled in low density polyethylene (LDPE) single-dose container.

II.2 Drug Substance

Both ipratropium bromide and salbutamol sulphate has monographs in the Ph Eur.

Ipratropium bromide is a white or almost white crystalline powder which is soluble in water. The structure of ipratropium bromide has been adequately proven and its physico-chemical properties sufficiently described. The route of synthesis has been adequately described and satisfactory specifications have been provided for starting materials, reagents and solvents. The active substance specification includes relevant tests and the limits for impurities/degradation products have been justified. The analytical methods applied are suitably described and validated.
Stability studies have been conducted and the data provided are sufficient to confirm the retest period.

Salbutamol sulphate is a white or almost white crystalline powder which is freely soluble in water. The structure of salbutamol sulphate has been adequately proven and its physico-chemical properties sufficiently described. The route of synthesis has been adequately described and satisfactory specifications have been provided for starting materials, reagents and solvents.
The active substance specification includes relevant tests and the limits for impurities/degradation products have been justified. The analytical methods applied are suitably described and validated.
Stability studies have been conducted and the data provided are sufficient to confirm the retest period.

II.3 Medicinal Product

Salipra nebuliser solution is formulated using excipients described in the current Ph Eur. All raw materials used in the product are of vegetable origin.

The product development has taken into consideration the physico-chemical characteristics of the active substance.
The manufacturing process has been sufficiently described and critical steps identified. Results from the process validation studies confirm that the process is under control and ensure both batch to batch reproducibility and compliance with the product specification.
The tests and limits in the specification are considered appropriate to control the quality of the finished product in relation to its intended purpose.
Stability studies under ICH conditions have been performed and data presented support the shelf life claimed in the SPC, with no special storage precautions.

III. NON-CLINICAL ASPECTS

III.1 Discussion on the non-clinical aspects

Since this product has been shown to be essentially similar and refer to a product approved based on a full application with regard to preclinical data, no further such data have been submitted or are considered necessary.

IV. CLINICAL ASPECTS

IV.1 Pharmacokinetics

The Guideline on the Requirements for Clinical Documentation for Orally Inhaled Products (OIP) Including the Requirements for Demonstration of Therapeutic Equivalence between Two Inhaled Products for Use in the Treatment of Asthma and Chronic Obstructive Pulmonary Disease (COPD) in Adults and for Use in the Treatment of Asthma in Children and Adolescents (CPMP/EWP/4151/00 Rev. 1) states that when solutions for nebulisation have the same qualitative and quantitative composition as the reference product the requirement for clinical studies may be waived. The applied product has the same qualitative and quantitative composition in active substances (ipratropium bromide and salbutamol sulphate) and the same qualitative composition in excipients except for the pH adjuster (sulphuric acid instead of hydrochloric acid) as the reference medicinal product. Thus the composition is nearly identical. The absence of clinical studies is accepted in line with the OIP guideline.

IV.2 Discussion on the clinical aspects

Since this product has been shown to be essentially similar and refer to a product approved based on a full application with regard to clinical efficacy/safety data, no further such data have been submitted or are considered necessary.

V. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND RECOMMENDATION

User consultation

A user consultation with target patient groups on the package information leaflet (PIL) has been performed on the basis of a bridging report making reference to Ipratropium Bromide+Salbutamol Sulfate 0.5mg + 2.5mg/2.5ml Inhalation vapour, Solution, IE/H/0163/001.
The bridging report submitted by the applicant has been found acceptable.

The risk/benefit ratio is considered positive and Salipra, 0.5 mg/2.5 mg, nebuliser solution, is recommended for approval.

VI. APPROVAL

Salipra, 0.5 mg/2.5 mg, nebuliser solution, was approved in the national procedure on 2015-02-26.

LÄKEMEDELSVERKET
MEDICAL PRODUCTS AGENCY

Public Assessment Report – Update

Scope	Procedure number	Product Information affected	Date of start of the procedure	Date of end of procedure	Approval/ non approval	Assessment report attached
						Y/N (version)

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.mpa.se E-mail: registrator@mpa.se